BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fellermeier-Kopf S, Gieseke F, Sahin U, Müller D, Pfizenmaier K, Kontermann RE. Duokines: a novel class of dual-acting co-stimulatory molecules acting in cis or trans. Oncoimmunology 2018;7:e1471442. [PMID: 30228940 DOI: 10.1080/2162402X.2018.1471442] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Murer P, Neri D. Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation. N Biotechnol 2019;52:42-53. [PMID: 30991144 DOI: 10.1016/j.nbt.2019.04.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 9.3] [Reference Citation Analysis]
2 Aschmoneit N, Kocher K, Siegemund M, Lutz MS, Kühl L, Seifert O, Kontermann RE. Fc-based Duokines: dual-acting costimulatory molecules comprising TNFSF ligands in the single-chain format fused to a heterodimerizing Fc (scDk-Fc). OncoImmunology 2022;11:2028961. [DOI: 10.1080/2162402x.2022.2028961] [Reference Citation Analysis]
3 Li H, Er Saw P, Song E. Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics. Cell Mol Immunol 2020;17:451-61. [PMID: 32313210 DOI: 10.1038/s41423-020-0417-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
4 Richards DM, Sefrin JP, Gieffers C, Hill O, Merz C. Concepts for agonistic targeting of CD40 in immuno-oncology. Hum Vaccin Immunother 2020;16:377-87. [PMID: 31403344 DOI: 10.1080/21645515.2019.1653744] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]